Table 2. Clinical Efficacy Outcomes at Week 12.
| Variable | Placebo, Mean (SEM) | 0.3-mg/kg Zilucoplan, Mean (SEM) | 0.3-mg/kg Zilucoplan vs Placebo | 0.1-mg/kg Zilucoplan, Mean (SEM) | 0.1-mg/kg Zilucoplan vs Placebo | ||
|---|---|---|---|---|---|---|---|
| Difference, Mean (SEM) | P Valuea | Difference, Mean (SEM) | P Valuea | ||||
| No. | 15 | 14 | NA | NA | 15 | NA | NA |
| QMG | –3.2 (1.2) | –6.0 (1.2) | –2.8 (1.7) | .05 | –5.5 (1.2) | –2.3 (1.7) | .09 |
| MG-ADL | –1.1 (0.9) | –3.4 (0.9) | –2.3 (1.3) | .04 | –3.3 (0.9) | –2.2 (1.3) | .05 |
| MG-QoL15r | –2.1 (1.7) | –5.9 (1.7) | –3.7 (2.4) | .06 | –7.4 (1.7) | –5.3 (2.4) | .02 |
| MGC | –3.3 (1.6) | –7.4 (1.6) | –4.1 (2.2) | .04 | –5.3 (1.5) | –2.0 (2.2) | .19 |
| QMG decrease ≥3, No. (%) | 8 (53.3) | 10 (71.4) | NA | .27 | 10 (66.7) | NA | .36 |
| Rescue received, No. (%) | 3 (20.0) | 0 | NA | .12 | 1 (6.7) | NA | .30 |
Abbreviations: MG-ADL, Myasthenia Gravis Activities of Daily Living; MGC, Myasthenia Gravis Composite; MG-QoL15r, Myasthenia Gravis Quality-of-Life Revised Scale; NA, not applicable; QMG, Quantitative Myasthenia Gravis.
a
One-sided P values.